Business
Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
JUPITER, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global
About this update from Dyadic International, Inc.
[{"type":"text","content":"JUPITER, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for the second quarter 2022 and host a corporate update conference call on Wednesday, August 10, 2022. Conference Call Information Date: Wednesday, August 10, 2022 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: 800-289-0720; International +1-646-828-8073 Conference ID: 1292996 Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1561590&tp_key=dd628adef2 An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above. If you have any questions that you would like to ask management during the Q&A session, please email [email protected] prior to the conference call. About Dyadic International, Inc. Dyadic International, Inc. is a global biotechnology company committed to building disruptive microbial production platforms including the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila) to enable the development and large-scale manufacture of biologics. Dyadic’s lead technology is based on an industrially proven microorganism (named C1), which is currently used to speed development and lower the manufacturing cost of biologic vaccines, drugs and therapeutic proteins for the human and animal health markets. The company is also developing other proprietary and patented biotechnologies and applications to develop and produce certain metabolites and other biologic products across diverse markets. With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, including its lead asset DYAI-100 COVID-19 vaccine candidate, as well as other...